SCHEMBL618161

SCHEMBL618161

NS(=O)(=O)c1ccc2cc(Nc3ccccc3)ccc2c1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SNCA P37840 2/20 0.71
LMNA P02545 1/20 0.65
ALDH1A1 P00352 1/20 0.61
CYP3A4 P08684 1/20 0.61
HPGD P15428 1/20 0.61
HSD17B10 Q99714 1/20 0.61
MEN1 O00255 2/20 0.57
KMT2A Q03164 2/20 0.57
NSD2 O96028 1/20 0.56
DUSP3 P51452 1/20 0.56
PTPN5 P54829 1/20 0.56
CASP7 P55210 1/20 0.56
CASP6 P55212 1/20 0.56
PTPN11 Q06124 1/20 0.56
CA2 P00918 8/20 0.55
CA1 P00915 7/20 0.55
CA9 Q16790 6/20 0.55
CA12 O43570 4/20 0.55
SOS1 Q07889 3/20 0.54
MAPT P10636 2/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28746782 0.90 LMNA (0.70) SNCALMNAALDH1A1CYP3A4HPGD
SCHEMBL11540311 0.86 SNCA (0.58) SNCALMNAALDH1A1CYP3A4HPGD
SCHEMBL8023015 0.85 CA1 (0.67) ALDH1A1HSD17B10MEN1KMT2ANSD2
SCHEMBL278412 0.83 SNCA (1.00) SNCALMNAALDH1A1CYP3A4HPGD
SCHEMBL29843770 0.83 SNCA (1.00) SNCALMNAALDH1A1CYP3A4HPGD
SCHEMBL29668447 0.83 SNCA (1.00) SNCALMNAALDH1A1CYP3A4HPGD
SCHEMBL29757686 0.83 SNCA (0.71) SNCALMNAALDH1A1CYP3A4HPGD
SCHEMBL11961726 0.81 ALDH1A1 (0.91) SNCALMNAALDH1A1CYP3A4HPGD
SCHEMBL193716 0.79 LMNA (1.00) LMNAMEN1KMT2ACA2CA1
SCHEMBL9839080 0.79 LMNA (0.82) LMNAALDH1A1MEN1KMT2ACA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10967096-B2 Tissue sealant compositions, vascular closure devices, and uses thereof MEDIBEACON INC. (US) 2021-04-06 US disclosed
US-10960104-B2 Tissue sealant compositions, vascular closure devices, and uses thereof MEDIBEACON INC. (US) 2021-03-30 US disclosed
US-10881759-B2 Tissue sealant compositions, vascular closure devices, and uses thereof MEDIBEACON INC. (US) 2021-01-05 US disclosed
US-20190192727-A1 TISSUE SEALANT COMPOSITIONS, VASCULAR CLOSURE DEVICES, AND USES THEREOF MALLINCKRODT INC. 2019-06-27 US disclosed
US-20190192728-A1 TISSUE SEALANT COMPOSITIONS, VASCULAR CLOSURE DEVICES, AND USES THEREOF MALLINCKRODT INC. 2019-06-27 US disclosed
US-20160331862-A1 TISSUE SEALANT COMPOSITIONS, VASCULAR CLOSURE DEVICES, AND USES THEREOF MALLINCKRODT INC. 2016-11-17 US disclosed
US-9433700-B2 Tissue sealant compositions, vascular closure devices, and uses thereof MEDIBEACON INC. (US) 2016-09-06 US disclosed
US-20120041479-A1 Tissue Sealant Compositions, Vascular Closure Devices, and Uses Thereof MEDIBEACON, INC. 2012-02-16 US disclosed
WO-2010129258-A2 TISSUE SEALANT COMPOSITIONS, VASCULAR CLOSURE DEVICES, AND USES THEREOF MALLINCKRODT INC. (US) 2010-11-11 WO disclosed
US-7297495-B2 Hybridization-triggered fluorescent detection of nucleic acids EPOCH BIOSCIENCES, INC. (US) 2007-11-20 US disclosed
US-20070166723-A1 Hybridization-triggered fluorescent detection of nucleic acids EPOCH BIOSCIENCES INC. (US) 2007-07-19 US disclosed
US-6951930-B2 Hybridization-triggered fluorescent detection of nucleic acids EPOCH BIOSCIENCES, INC. (US) 2005-10-04 US disclosed
US-20030113765-A1 Hybridization-triggered fluorescent detection of nucleic acids EPOCH BIOSCIENCES, INC. (US) 2003-06-19 US disclosed
US-6472153-B1 COVALENTLY BOUND OLIGONUCLEOTIDE/MINOR GROOVE BINDER/LATENT FLUOROPHORE COMBINATION EPOCH BIOSCIENCES, INC. 2002-10-29 US disclosed
EP-1224332-A1 HYBRIDIZATION-TRIGGERED FLUORESCENT DETECTION OF NUCLEIC ACIDS Epoch Biosciences, Inc. (US) 2002-07-24 EP disclosed
WO-2001031063-A1 HYBRIDIZATION-TRIGGERED FLUORESCENT DETECTION OF NUCLEIC ACIDS EPOCH BIOSCIENCES, INC. (US) 2001-05-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070166723-A1 Hybridization-triggered fluorescent detection of nucleic acids DDX21, RNGTT, NOP2 SNCA 3959/4885LMNA 347/4885ALDH1A1 3480/4885
US-20030113765-A1 Hybridization-triggered fluorescent detection of nucleic acids DDX21, RNGTT, NOP2 SNCA 3959/4885LMNA 347/4885ALDH1A1 3480/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.